Last reviewed · How we verify

NCT04377607

Haemoglobin Concentration on COVID-19

Status unknown Last updated 16 September 2020
What this trial tests

trial testing File scanning in Corona Virus Infection in 200 participants. Status unknown.

Timeline
1 November 2020
Primary endpoint
20 November 2020
30 December 2020

Quick facts

Lead sponsorNevsehir Public Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment200
Start date1 November 2020
Primary completion20 November 2020
Estimated completion30 December 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Nevsehir Public Hospital

Who can join

Eligibility, any sex, with Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A rapid oxygen desaturation has observed in patients with COVID-19 which have seriously respiratory failure and most of them have intubated and connected to the mechanical ventilator. Finally, many of them have died during the process. ORF8 and superficial glycoproteins of a novel coronavirus bind to porphyrin on haemoglobin molecules and inhibit heme metabolism in an erythrocyte. However, it is not clarify the effects of the novel coronavirus on mean corpuscular volume (MCV), mean corpuscular of haemoglobin (MCH) and mean corpuscular haemoglobin concentration (MCHC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Corona Virus Infection

Currently open trials in the same condition.

Other Nevsehir Public Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04377607.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing